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Abstract: Morphogens, as intercellular signalling proteins, provide a non-cell-autonomous mechanism to impart 
positional information to cells and govern essential cellular processes such as apoptosis. Individual morphogen pathways 
utilise diverse strategies to regulate the assembly and activity of the pro-apoptotic multi-protein complexes – namely the 
apoptosome and the death-inducing signalling complex (DISC). This review aims to highlight the apoptotic regulatory 
mechanisms utilised by the Hedgehog (HH) morphogen pathway – with particular emphasis on a novel Caspase-9 
activating complex and the utilisation of a pro-apoptotic autocrine-signalling loop. 
Keywords: Hedgehog, apoptosis, BMP, dependesome, patched, smoothened, morphogen. 
INTRODUCTION 
 Apoptosis and morphogen signalling exhibit an intimate 
relationship. Both are essential for creating, and subsequently 
maintaining, adult animals, while aberrations in their activities 
are detrimental. At a functional level apoptosis can promote 
morphogen expression [1] and morphogen signalling can both 
promote or suppress apoptosis. An ability to modulate apoptotic 
and cell-survival pathways places them as key regulators of life 
and death. Although the majority of research has highlighted 
morphogens' roles in co-ordinating proliferation and 
differentiation in organismal development, more recent efforts 
have begun to identify the complex molecular mechanisms 
associated with morphogen-mediated apoptotic regulation. 
1. Apoptosis 
 The majority of apoptosis occurring throughout 
development removes unnecessary, but otherwise normal 
cells [2], while apoptosis in the adult primarily removes 
damaged, defective [3] or infected cells [4]. Hence, cell 
death is initiated in response to a large number of different 
developmental cues and cellular insults. Distinct intrinsic or 
extrinsic cellular signalling pathways are activated in 
response to molecular instructions or stress signals received 
from the cells’ interior or exterior, respectively. The intrinsic 
pathway is predominantly activated in response to cell-
autonomous apoptotic signals generated from within the cell 
[5] (e.g., DNA damage, anoxia and oncogene-activation). In 
contrast the extrinsic pathway is activated in response to 
recognition of extracellular ligands by cell-surface receptors 
(e.g., Fas [6]). In this manner neighbouring or infiltrating 
cells produce ligands to induce the death of another cell. 
However, cells may also autonomously produce, release and 
react to their own extrinsic death signals [7]. Ligand- 
mediated receptor activation leads to activation of down-
stream signalling pathways that in turn lead to caspases- 
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activation [6]. Therefore, extracellular-based instructions can 
govern the ultimate fate of a cell within an organ or tissue - a 
statement that is also applicable to morphogens. 
 Regardless of the type or source of apoptotic signal, 
caspases, a group of aspartate-directed proteases, lie at the 
heart of the cells' core death machinery [8]. Both the intrinsic 
and extrinsic pathways activate caspases, which in turn 
protealytically activate pro-apoptotic and disable anti-
apoptotic proteins [9]. This caspase-orchestrated cleavage of 
apoptotic regulators ultimately results in cleavage of 
essential regulators of cellular and genomic integrity [9]. To 
prevent an inflammatory response, the cell's remains are 
packaged into membrane bound apoptotic bodies and 
subsequently engulfed by macrophages and neighbouring 
cells [10]. 
2. Morphogens 
 At a molecular level morphogens can be described as 
molecules that emanate from a localised source to form a 
concentration gradient. While at a functional level they act as 
core organisers of cell patterning, cell fate and ultimately 
overall tissue morphology [11]. These morphogen-co-
ordinated events, incorporating growth, proliferation and cell 
death permit the exceptional three-dimensional structural 
complexity of organs. 
 Of the known morphogens, Bone Morphogenic Proteins 
(BMPs) [12], Notch [13], Wnts [14] and Hedgehog [15] 
family members are evolutionary conserved. All four share 
an ability to (A) act directly on a cell through, in most cases, 
receptor engagement to elicit (B) qualitatively distinct 
cellular outcomes in response to different morphogen 
concentrations/gradients. Therefore a cell's position within a 
morphogen concentration gradient determines the state of the 
cell’s intracellular signalling pathways and gene expression 
profiles. Intriguingly, through distinct mechanisms, 
morphogen-associated signalling pathways can instigate, as 
well as suppress, apoptosis (see following sections). 
Unsurprisingly, defects in these potent signalling pathways 
manifest in numerous diseases and developmental defects 
[16]. 
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 The ability of a morphogen to confer distinct cellular 
fates is effected by the cells’ ability to perceive quantitative 
differences in the slope as well as the absolute concentration 
of the ligand [17, 18]. Morphogen receptors, unlike more 
conventional binary “on/off” receptors, are capable of 
translating quantitative differences in ligand levels/gradients 
into distinct cellular outcomes. In most cases, differences in 
morphogen concentrations affect the activation level/specific 
activity of key transcriptional effectors. And it is these 
differences in transcription factor activities that initiate 
differential patterns of gene expression and determine 
cellular outcomes. Hence morphogens represent potent and 
complex intercellular signalling molecules whose message is 
interpreted in a context-specific manner. 
 In a developing tissue individual cells encounter 
combinations of different morphogen gradients. Integration 
of this information by a cell is further influenced by cross-
talk and cross–regulation between different morphogen- and 
non-morphogen-signalling pathways [19]. Cross-talk 
between pathways occurs at the level of target genes – for 
example WNT [20], Notch [21] and Hedgehog [22] 
pathways promote, while BMP pathways [23] repress MYC 
expression. Cross-regulation of one morphogen’s expression 
by another is a frequently used mechanism and the example 
of Hedgehog-mediated expression of pro-apoptotic BMPs 
will be discussed later. 
 Due to the sheer breadth of morphogen research, this 
review will focus upon the pro and anti-apoptotic signalling 
functions of the Hedgehog family of morphogens: 
Drosophila Hedgehog (HH) and vertebrate Sonic-, Desert- 
and Indian-Hedgehog (SHH, DHH and IHH, respectively). 
Please note that in the text the HH pathway denotes a 
generalised Hedgehog-family-member pathway, not just that 
of the Drosophila HH. Overall, this review aims to focus on 
HH’s ability to influence multiple apoptotic signalling 
pathways and its relevance to disease and development. 
3. Canonical HH Signalling Pathway 
 The canonical HH-pathway governs the majority of 
Hedgehog's mitogenic and morphogenic effects [16] (Fig. 1) 
and acts through regulating the activity of Smoothened 
(SMO) [24] - a seven-transmembrane G-protein coupled 
receptor-like protein. In the absence of HH, Patched (PTC), 
Hedgehog’s cognate 12-transmembrane receptor protein 
[25], blocks SMO and as a consequence represses the 
downstream signalling pathway (Fig. 1). Upon binding of 
HH to PTC, SMO is derepressed and activates a signalling 
cascade of post-translational modifications [15] that 
promotes activation of a family of Glioma-associated 
oncogene homolog (GLI) transcription factors [26]. These in 
turn transcriptionally activate the pathway's target genes that 
include those involved in cell cycle entry [27], proliferation 
[22], angiogenesis [28], axonal guidance [29] and epithelial-
 
Fig. (1). Basic Overview of the PTC- and SMO-associated Signalling Pathways and their Cellular Outcomes. PTC governs the activity 
of a pro-apoptotic pathway (red square), while SMO governs the activity of the canonical elements of the HH-pathway, including the 
indicated non-apoptotic cellular outcomes (blue square) and pro- and anti-apoptotic (green square) signalling pathways. HH – Hedgehog; 
PTC = Patched; SMO = Smoothened. Anti- and pro-apoptotic proteins (round-edged squares) are labelled green and red respectively. 
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mesenchymal transition [30]. 
 Vertebrates encode three family members [31]: GLI-1 (a 
potent transcriptional activator), -2 (transcriptional activator 
and repressor functions) and -3 (predominantly a 
transcriptional repressor). In an unstimulated cell GLI-1 is 
not expressed and GLI-2 and -3 are protealytically processed 
and converted into transcriptional repressors. GLI-2 and -3 
are maintained in their repressor forms through 
phosphorylation-mediated ubiquitylation and subsequent 
cleavage [32]. Upon HH stimulation, both GLI-2 and 3 are 
no longer cleaved and GLI-1 is now expressed. Together the 
lack of GLI-2 -3-mediated transcriptional repression, 
conversion of GLI-2 into an activator and expression of GLI-
1 results in transcriptional activation of target genes. 
4. Role of Canonical Pathway in Apoptosis 
 Activation of the canonical Hedgehog pathway can 
suppress apoptosis through transcriptional upregulation of 
potent inhibitors of both the extrinsic and intrinsic apoptotic 
pathways. Hence, aberrant HH signalling in human tumours 
provides an effective means of evading apoptosis. For 
example basal cell carcinomas are subjected to apoptotic 
signals due to expression of the pro-apoptotic TRAIL 
(Tumour necrosis factor-Related Apoptosis-Inducing 
Ligand) ligand and its receptors, TRAIL receptor 1/2 (also 
called DR4 and DR5, respectively) [33]. However, they also 
harbour mutations in SMO or PTC that result in ligand-
independent activation of the canonical HH signalling 
pathway [34]. Resulting in a reduction of cells’ ability to 
either promote pro-, or suppress anti-apoptotic pathways. 
One repressed target of the pathway is the TRAIL receptor 1 
and HH-mediated expression of FLIP (FLICE-Like 
Inhibitory Protein) [33] blocks TRAIL-mediated activation 
of Caspase-8 and hence the apoptotic caspase cascade. 
Similarly HH-mediated Bcl2 overexpression [35, 36] also 
blocks the tumours’ increased apoptotic load generated by 
oncogene activation and increased metabolic stress [37]. As 
a potent anti-apoptotic protein frequently overexpressed in 
numerous cancers, Bcl2 acts to prevent the release of 
cytochrome c from the mitochondria [38] (and Grant 
Dewson’s review in this issue). This in turn prevents 
cyctochrome-c-mediated apoptosome formation, Caspase-9 
activation and initiation of the apoptotic caspase cascade. 
Therefore a combination of potent apoptotic inhibitors, 
induced by the HH pathway, would render cells impervious 
to two major routes of apoptotic induction. 
 In addition to the anti-apoptotic transcriptional targets, 
the canonical HH signalling pathway may also use post-
translational modifications to regulate the levels and activity 
of the central apoptotic regulator p53. HH-mediated 
activation of SMO may promote PI3K-mediated activation 
of the anti-apoptotic AKT pathway [39] and promote 
MDM2-mediated p53 degradation [40]. Removal of p53, a 
key integrator of diverse apoptotic signals, again would 
cause cells to resist many types of apoptotic insults. 
 The HH pathway’s ability to protect cells from both 
intrinsic, through Bcl2, loss of p53 and activation of cell 
survival pathways, and extrinsic mechanisms, through FLIP, 
highlights its role as a central player in apoptotic regulation. 
Therefore, in combination with its more established role in 
promoting cell growth and division, aberrant activation of 
the canonical HH pathway can provide both the drive 
towards, and inhibition of the pro-apoptotic brake(s) against, 
tumourigenesis. Nevertheless, the HH pathway has 
additional pro- and anti-apoptotic regulatory roles that will 
be discussed in the following sections. 
5. Hedgehog's Anti-Apoptotic Role in Development 
 A number of elegant developmental studies with mice 
and chicken have revealed a major anti-apoptotic role for HH 
in a range of cells within different tissues. Midline cells 
(notochord and floorplate) in developing chick [41-43] and 
mouse [44-46] embryos provide SHH-derived survival and 
proliferative signals to the surrounding tissue. Surgical 
procedures that prevent regression of Hensen's node (the 
avian organiser) prevent the formation of the midline cells, 
but allow the formation the neural tube [41]. In the absence 
of midline cells - the source of SHH - all the tissue 
surrounding the midline-depleted region, including the 
neural tube, undergo apoptosis. This massive cell death 
could be rescued by grafting of SHH expressing cells in the 
midline-depleted animal [41]. Similar observations were also 
made for midline-derived SHH in promoting the survival of 
myogenic and chondrogenic cell lineages [43]. 
 In the mouse, ectopic expression of SHH in the dorsal 
neural tube inhibits differentiation and increased cell 
numbers [47]. Mice deficient in Shh exhibit gross defects in 
patterning and tissue organisation and only survive up to or 
just after birth [45]. Loss of SHH expression in a Shh null 
animal led to extensive somite and neural crest cell death 
[45, 48]. In contrast, loss of Ptc function leads to overgrowth 
phenotypes in both homozygous mouse embryos and 
heterozygous adults [49]. These observations are consistent 
with a role for PTC in both promoting cell death and 
suppressing proliferation. Furthermore, injection of SHH 
blocking antibodies in the cephalic region of chick embryos 
led to massive apoptosis in the neural tube and neural crests 
regions  [50, 51]. 
6. SHH as a Survival Factor in Tumour Cells 
 Therapeutic intervention to block the HH pathway and its 
ability to suppress apoptosis, differentiation and promote 
proliferation has proven extremely effective in the treatment 
of a number of human tumours [52]. Hedgehog’s mode of 
action may be cell autonomous or cell non-autonomous, 
acting in either an autocrine or paracrine manner, 
respectively [53]. In an autocrine model tumour cells both 
produce and respond to HH, while in the paracrine model 
HH produced by the tumour signals to the surrounding 
stroma. These stromal cells can then indirectly benefit the 
tumour cells by, for example, mediating angiogenesis [54]. 
A reverse paracrine model may also function where tumour 
cells drive tumourigenesis by actively signalling to 
surrounding stromal cells to produce HH. Furthermore, HH 
signalling to the stroma may in turn promote production of 
alternative extracellular signalling molecules such as Insulin-
like growth factor (IGF) [55] and directly promote tumour 
growth and/or survival. 
 Basal cell carcinoma provided direct evidence for a role 
for HH in human cancer. Patients harbour mutations in either 
PTC or SMO that render pathway activation ligand 
independent [34]. This HH-independent method of activating 
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the pathway seems to be rare in other tumour types, with the 
majority of tumours being dependent on either autocrine or 
paracrine modes of actions [56]. Numerous studies have 
identified HH-signalling as being essential to the survival of 
tumour cells derived from a wide variety of tissues: small 
cell lung cancer [57]; oesophageal, stomach, biliary tract and 
pancreatic cancers [58, 59], multiple myeloma [60, 61], 
leukemias [62] and gliomas and other brain tumours [63]. 
Furthermore, in Helicobacter pylori induced gastric cancer, 
gastric epithelial cells reactivate expression of SHH and, 
through an autocrine loop, confers resistance to apoptosis 
[64]. 
7. Pro-Apoptotic Role of SHH 
 While generally considered to be a survival signal, SHH 
also seems to play a pro-apoptotic role in some 
developmental death processes. Cells eliminated at the 
fusion of the neural folds require SHH-mediated apoptosis, 
while certain cells in the spinal cord exhibit apoptotic 
responses to SHH signalling [65]. Furthermore, in the chick 
developing limb bud, SHH expressing cells in the zone of 
polarising activity undergo SHH-mediated homeostatic 
apoptosis. This action is key to maintain the correct spatial 
positioning and prevent the overexpansion of the zone of 
polarising activity [66]. Programmed cell death occurring in 
the developing vertebrate limb is one of the clearest 
examples of apoptosis as a morphogenetic process [67]. 
Similarly, the morphogenic role of HH is extremely well 
characterised [68]. Its exclusive expression in a distinct 
“polarising region” establishes a morphogen gradient 
essential for the correct growth and patterning of the 
vertebrate limb. Within the developing limb four clear areas 
undergo massive apoptosis that control digit formation and 
separation - namely the opaque patch, anterior-, and the 
posterior-necrotic zones and interdigital areas [69]. 
 In the posterior-necrotic zone, exogenous SHH promotes 
apoptosis but suppresses death in three other regions [66]. 
Such radical differences in cellular fate most likely reflect 
differences in an individual cell’s position within a HH 
concentration gradient and/or the integrated actions of other 
extracellular signalling pathways. Although in the minority, 
similar pro-apoptotic effects of exogenous SHH occur in the 
avian spinal cord that result in a loss of neuronal precursor 
cells and floor plate cells [65]. 
 Recent work with conditional Ptc knockout mice 
revealed the importance of paracrine HH signalling in the 
control of haematopoiesis [70]. Deleting Ptc in 
haematopoietic cells did not lead to activation of the HH 
pathway or generate a phenotype. Conversely, loss of Ptc in 
the surrounding non-haematopoietic cells led to autonomous 
HH pathway activation and correlated with apoptosis of 
haematopoietic early T- and B-cell precursors. 
8. Patched, the Hedgehog Receptor as a Pro-Apoptotic 
Dependence Receptor 
 With the exceptions of the few examples given above, 
the majority of evidence points to a role for the canonical 
pathway, via SMO, in suppressing apoptosis. However, more 
recent work however has highlighted a role for PTC in pro-
apoptotic signalling, independent of the SMO-associated 
canonical pathway [41, 71]. These findings demonstrate a 
bifurcation of the Hedgehog signalling pathway downstream 
of the PTC receptor into canonical and non-canonical 
branches (see Fig. 1). Furthermore they suggest that HH-
mediated regulation of apoptosis simultaneously relies on 
regulation of separate intracellular signalling pathways 
governing (A) PTC-mediated pro-apoptotic signalling and 
(B) SMO-mediated anti-apoptotic signalling. 
 PTC’s pro-apoptotic function in the absence of HH 
places PTC as a member of a family of "dependence 
receptors" [72]. The family includes: DCC (deleted in 
colorectal cancer), TrkC (tyrosine kinase receptor C), ALK 
(anaplastic lymphoma kinase), RET (rearranged during 
transfection), ?v?3 integrin, p75NTR (p75 neurotrophin 
receptor), neogenin, and androgen receptor. These proteins 
along with PTC are grouped by their shared properties/ 
abilities to: (1) induce cell death in the absence of their 
cognate ligand; (2) induce caspase-dependent cell death; (3) 
undergo a pro-apoptotic modification/alteration of a 
cytoplasmic domain; (4) play a role in both developmental 
processes, most commonly neurogenesis, and cancers; and 
(5) potentially contain a dependence receptor associated 
transmembrane motif (DART) [73]. PTC matches all five of 
the above criteria and may explain some of the apoptotic 
response of cells deprived of HH. 
 PTC overexpression, in the absence of SHH, activates 
caspases, promotes DNA fragmentation and is suppressed 
with the pan-caspase inhibitor z-VAD [41]. PTC deletion 
and mutation analyses identified a region in the seventh 
intracellular loop of PTC essential for its apoptotic 
signalling. Furthermore this region promotes the formation 
of a pro-apoptotic multiprotein complex named the 
"dependosome" [71]. Within this region of murine PTC 
resides a caspase cleavage site (PETD
1392?H) [41] and 
cleavage at this site by the effector Caspase-3 and -7, or 
initiator Caspase-8 was required for PTC-mediated 
apoptosis. Expression of the amino-terminal cleaved portion 
(PTC
1-1392
) was sufficient to induce apoptosis and was 
refractory to SHH-mediated protection. Moreover a non-
caspase-cleavable mutant, PTC PETN
1392
H, was unable to 
promote cell death. 
 More recent molecular analysis of PTC receptor 
complexes identified a number of apoptotic and caspase-
associated proteins [71] (Fig. 2). Within this complex reside 
the initiator Caspase-9, the LIM-domain-containing DRAL 
(Down-regulated in Rhadomyosarcoma) and the CARD-
containing proteins TUCAN (tumour-up-regulated CARD-
containing antagonist of Caspase nine) and NALP1 (NLR 
family, pyrin domain containing 1). DRAL bridges PTC to 
TUCAN, which in turn recruits Caspase-9. The presence of 
this initiator caspases within the complex provides an 
obvious link to the intrinsic apoptotic pathway. In the 
absence of SHH, the multiprotein complex including 
Caspase-9 assembles and leads to activation of the 
downstream caspase-cascade. While in the presence of SHH 
caspases are not activated, the multiprotein complex 
dissembles and cells do not die. 
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 While Caspase-9 provides the most obvious link to 
apoptosis [5], the other multi-protein complex components 
also have links to apoptotic regulation (see following section 
for more details). Intriguingly, DRAL, TUCAN and NALP1 
have known roles in the regulation the NF?B pathway [74]. 
This pathway has a complex association with apoptosis as it 
both promotes and suppresses cell death [75]. Nevertheless 
this link between PTC and the Nf?B pathway provides a 
potential molecular mechanism for PTC-mediated apoptosis. 
As a number of the proteins identified in the 'dependosome' 
have been linked to alternative apoptotic and caspase-
activational pathways, it is possible that the dependosome 
 
Fig. (2). The Dependosome Multi-protein Complex and its Downstream Effectors. In the absence of HH, PTC binds DRAL, which 
recruits TUCAN, NALP1 and potentially TRAF6. Both TUCAN and NALP1 can regulate inflammatory mediators and pro-apoptotic caspase 
activation. Inflammatory caspases (Inflam Caspases) activate the NF?B pathway and in certain circumstances a specific form of apoptosis 
called pyroptosis. In addition to acting as a scaffold, DRAL can also enhance FOXO transcriptional activity and activate caspases. TRAF6, if 
present in the complex, can influence pro- and anti-apoptotic signalling through JNK and AKT, respectively. PTC = Patched; DRAL = 
Down-regulated in Rhadomyosarcoma; TRAF6 = TNF Receptor Associated Family 6; TUCAN = Tumour-up-regulated CARD-containing 
Antagonist of Caspase Nine; NALP1 = NLR family, pyrin domain containing 1; FOXO = Forkhead Box Class O); AKT = AK-strain 
Transforming or Protein Kinase B; JNK = Jun N-terminal Kinase; Nf?B = Nuclear Factor Kappa B. Anti- and pro-apoptotic proteins (round-
edged squares) are labelled green and red respectively. Please note, in this scenario TRAF6 is considered pro-apoptotic and Nf?B is 
considered anti-apoptotic. 
14    The Open Cell Signaling Journal, 2011, Volume 3 Mark Ditzel 
may act as a central hub for activating multiple, independent 
routes for apoptotic initiation. 
8.1. Apoptosis-Associated Roles of PTC Dependosome 
Subunits 
8.1.1. DRAL/FHL2 
 DRAL/FHL2 is a four and a half LIM domain containing 
protein that primarily acts as a transcriptional co-activator or –
repressor for a number of target genes [76, 77]. Caspase-
mediated cleavage of PTC is essential for its pro-apoptotic 
activity and its interaction with the LIM2-containing region of 
DRAL [71]. Upon overexpression, DRAL promotes apoptosis 
in a number of cell lines and fits with its role as a p53 target 
gene [78]. In addition to its above-mentioned role in recruiting 
Caspase-9, mechanistically, FHL2 may be affecting apoptosis 
through recruitment of TRAF6 and its associated apoptosis-
regulatory complexes [79]. Both pro-apoptotic TGF?- and 
RANK-receptors recruit TRAF6, which in turn activates TAK1 
and leads to increased JNK activity [80, 81]. As with the HH 
pathway, under certain circumstances the RANK- and TGF?-
receptors can provide anti-apoptotic signals. Both TGF? [82] 
and RANKL [83] use TRAF6 and SRC to mediate anti-apopto-
tic signalling through the PI3K/AKT survival pathway [84]. 
 An alternative link to apoptosis includes FHL2’s ability 
to bind the pro-apoptotic Forkhead transcription factor 
FOXO1 and blocks its transcriptional activity [85]. While 
FHL2 also acts on other transcriptional regulators including 
SMADs 2, 3 and 4 [86] and ?-catenin [77] to regulate key 
cell cycle regulators. FHL2 could also act to suppress 
survival signalling through binding integrins and blocking 
integrin-mediated ERK signalling [87]. 
8.1.2. TUCAN/CARD8 
 TUCAN is a CARD-containing protein that is expressed 
as 48kDa and 54kDa isoforms. Through a homophilic 
CARD-CARD interaction, the smaller form binds Caspase-9 
and blocks a variety of intrinsic-pathway activating insults 
[88, 89]. In contrast the 54kDa, which contains a unique 
amino-terminus absent in 48kDa form, binds FADD and 
blocks FasL- and extrinsic Caspase-8-mediated apoptosis 
[89]. Nevertheless, contradictory findings suggest that 
TUCAN can also assume pro-apoptotic roles. Upon 
overexpression TUCAN blocked Caspase-1 processing, the 
production of IL1-?, suppressed the NF?B pathway and 
ultimately sensitised cells to PMA-induced apoptosis [90]. 
8.1.3. NALP1 
 NALP1 is a member of the NOD-like receptor family 
involved the recognition of viruses and microbes and 
subsequent activation of the innate immune system [91]. At 
the molecular level NALPs promote the formation of large 
multi-protein signalling complexes called inflammasomes 
that activate inflammatory Caspases-1, -4 and -5 [92]. While 
inflammatory caspases are associated with apoptosis of 
infected macrophage apoptosis - called pyroptosis [93] – 
these caspases are predominantly involved in processing 
inflammatory cytokines such as Interleukin-1? and -33 and 
promoting the inflammatory response [94]. Upon processing, 
interleukins - as extracellular signalling molecules - bind 
their cognate receptors and, in an autocrine or paracrine 
manner, activate the NF?B pathway [95]. 
 In addition to NALP1’s role in the inflammasome, it also 
binds to the anti-apoptotic Bcl2 and Bcl-XL proteins [96]. 
These interactions repress NALP1-mediated Caspase-1 
activation, however the affect on Bcl2 and Bcl-XL's anti-
apoptotic activity remains unknown. Nevertheless, a clear 
role for NALP1 in promoting apoptosis comes from its 
ability to interact with the pro-apoptotic apoptosome 
component Apaf-1 and promote cell death [97]. 
9. Hedgehog-Mediated Apoptosis via a BMP-Autocrine Loop 
 In addition to the role of PTC in dependosome-signalling, 
a second canonical-pathway-associated apoptotic pathway 
can also promote Caspase-9 activation. In the absence of 
HH, the cleaved GLI-3
R
 repressor form mediates some of the 
ectopic apoptosis seen in the neural tube and developing 
limbs [46, 98, 99]. Aberrant neural tube cell and developing 
limb apoptosis seen in Shh null mice is rescued in a Shh
-/-
;Gli-3
-/-
 null animal [46]. Therefore, with respect to cell 
survival, the canonical SHH pathway primarily acts to 
prevent the processing of full-length GLI-3 into its cleaved 
GLI-3
R
 form. A number of observations correlate increased 
levels of apoptosis with increased expression of GLI-3
R
 and 
the morphogen BMP4 [98, 99]. Apoptosis associated with 
BMP signalling occurs in a number of tissues throughout 
development and includes the developing limb buds [67]. 
One mechanism acts to activate Caspase-9 through 
stabilisation of p53 and subsequent expression of the pro-
apoptotic BH3-only proteins PUMA [100] or BIM [101]. 
 GLI-mediated transcriptional activation of BMP4 and 
BMP7 promoters [102] provides a direct molecular link 
between the HH and BMP morphogen pathways. Therefore, 
when depleted of ligand, the HH pathway is unable to prevent 
the formation of GLI-3
R
, which in turn leads to production of 
BMPs. Additionally, in the presence of ligand, HH signalling 
upregulates expression of the BMP antagonist Gremlin [98]. 
During limb morphogenesis, this BMP-binding protein's exp-
ression correlates with a lack of apoptosis and, in its absence, 
with cell death. In the developing duck embryo, non-apoptotic 
interdigital tissue expresses Gremlin, while the apoptotic inter-
digital tissue of a chick lacks it [103]. Therefore in the absence 
of SHH, a combination of events promotes BMP-mediated apo-
ptosis: (1) by increased production of BMP4 ligand and (2) 
decreasing levels of its inhibitory binding-protein Gremlin (Fig. 
3). 
 The above example demonstrates that when active one 
morphogen pathway (HH) directly suppresses ligand 
production of another (BMPs). In turn, when active the BMP 
pathway represses the expression a third, anti-apoptotic 
associated morphogen, Fibroblast Growth Factor 8 (FGF8). 
Therefore, through regulating BMP expression, the HH 
pathway indirectly promotes FGF8 expression [104]. In the 
Shh
-/-
 null mouse, apoptotic cells in or around apoptotic 
tissues not only show elevated levels of BMP 4/7, but also 
lack FGF8 expression [105]. In the interdigital regions of the 
developing limbs, FGF8 acts as a cell survival factor [106]. 
Inactivation of FGF8 results in ectopic cell death in the 
development of the early limb bud [107, 108], kidney [109, 
110] and brain [111, 112]. Activation of both RAS-MAPK 
and PI3K-AKT cell survival pathways are associated with 
the FGF receptors engagement [113] and therefore provides 
a powerful means to control apoptosis. 
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Fig. (3). Overview of Apoptotic Regulation by the HH-pathway. SMO activates the Hedgehog signalling kinase complex (HSKC) [119] 
that in turn promotes anti-apoptotic actions through GLI-1 and -2 and suppresses pro-apoptotic actions through GLI-3
R
. The GLI-1 and-2 
pathway induces the expression of inhibitors of the intrinsic (Bcl2), extrinsic (FLIP) and GLI-3
R
-regulated BMP4/7-autocrine (Gremlin) 
apoptotic pathways. These distinct apoptotic pathways regulate the indicated Core-death-machinery complexes (red circles = Dependosome, 
Death Inducing Signalling Complex (DISC) and Apoptosome). All three complexes activate initiators caspases, which in turn activate 
effector caspases and mediate apoptosis. GLI-3
R
 governs a pro-apoptotic autocrine-signalling loop, by transcriptionally upregulating Bone 
Morphogenic Proteins 4/7 (BMP4/7). These then bind the Bone Morphogenic Protein Receptor 1 (BMPR1), repressing FGF8 expression and 
activating JNK. Phosphorylation of JNK substrates leads to inhibition of the anti-apoptotic molecules Bcl2 (B-cell lymphoma/leukaemia 2 
gene) and FLIP (Flice/Caspase-8-Inhibitory Protein) – see text for details. Anti- and pro-apoptotic proteins (round-edged squares) are 
labelled green and red respectively. Please see Figure 2 for a more detailed schematic of the Dependosome. 
16    The Open Cell Signaling Journal, 2011, Volume 3 Mark Ditzel 
 At the molecular level, BMP-signalling through ligand 
engagement of the BMP receptor (BmpR1A) mediates loss 
of FGF8 expression [105]. While this provides a molecular 
link between the two morphogen-signalling pathways, it is 
unlikely to be the sole apoptotic consequence of elevated 
BMP signalling. As with the SHH receptor PTC, ligand 
engagement of BMP-family Transforming Growth Factor ? 
receptors (TGF-?R) affects two distinct downstream 
signalling pathways. One relies on a transcriptional output 
mediated by a group of transcriptional co-regulators called 
SMADs [114]. Upon binding of the TGF? ligand, TGF?RI- 
and TGF?RII-receptors activate SMADs and sensitise cells 
to apoptosis by transcriptionally downregulating anti-
apoptotic BCL-2 [115] and upregulating pro-apoptotic BIM 
[116]. 
 In addition to a SMAD-mediated transcriptional response, 
post-translational modifications can also drive TGF?-
mediated apoptotic responses. Upon TGF?-receptor ligation, 
TG?R-mediated phosphorylation activates the E3 ubiquitin-
protein ligase TRAF6 and promotes its non-degradative 
K63-linked autoubiquitylation [80]. TGF-?-activated kinase 
1 (TAK1) is then activated upon binding to ubiquitylated 
TRAF6. Once active TAK1 initiates a kinase cascade to 
activate the stress-activated kinases JNK and p38 [81] (see 
Fig. 3). These kinases are capable of promoting both 
developmental and stress-induced apoptosis and are 
activated in response to a range of cellular insults [117]. As 
discussed earlier PTC may also recruit TRAF6 via FHL2 to 
activate JNK/p38 and promote apoptosis. Regardless of the 
route of JNK/p38 activation, these kinases effect apoptosis 
[117, 118] via (1) nuclear translocation of c-JUN and 
subsequent expression of pro-apoptotic genes; (2) direct 
phosphorylation and activation of p53; (3) degradation of 
FLIP, via phosphorylation and activation of the ubiquitin-
protein ligase ITCH; and (4) activation and suppression of 
pro-apoptotic BH3-only protein and anti-apoptotic Bcl2 
family members, respectively. 
CLOSING REMARKS 
 In summary, components of the HH-pathway can both 
directly promote and suppress apoptosis (Fig. 3). 
Unfortunately, a clear link between the presence, or absence, 
of ligand and promotion or suppression of apoptosis cannot 
currently be made. In the presence of ligand the HH-pathway 
can actively suppress apoptosis through both blocking pro- 
and activating anti-apoptotic proteins. However, under 
certain developmental circumstances, the presence of HH 
and activation of the pathway promotes apoptosis (see 
Section 8). Nevertheless, in the absence of ligand, apoptosis 
does seem to predominate, with two separate signalling 
pathways converging on caspases to promote cell death. The 
first stems from PTC-mediated formation of the 
"dependosome", which should prompt the apoptotic field to 
rethink the exclusive association between extracellular 
(extrinsic) pathways and Caspase-8 activation. And the 
second stems from SMO-associated processing of GLI-3 into 
its GLI-3
R
 form. These two pathways significantly differ, 
with the former directly activating Caspase-9 and the latter 
acting indirectly through autocrine action of second 
messengers (BMPs). 
 With the majority of our knowledge being derived from 
in vivo animal studies, such results reflect the complex 
environment an individual cell experiences in a particular 
tissue and timeframe. Within these settings individual cells 
perceive temporally and spatially restricted instructions from 
a wide array of extracellular signalling molecules (see 
Review by Paul Ekert in this issue) - that include 
morphogens. In the case of morphogens, cellular responses 
are not only dependent on the presence or absence of the 
ligand, but also slope of the ligand gradient. In combination 
with the other extracellular signalling molecules, cells must 
translate and integrate this information through intracellular 
pathways. These in turn initiate molecular programmes that 
effect cellular outcomes. Due to a significant degree of 
cross-talk and cross-regulation between different pathways 
[19] the molecular and cellular outcomes of morphogen-
stimulation can be altered. Such contextual determinants 
may help explain the apparent pro- and anti-apoptotic duality 
of HH-signalling. Only more detailed in vivo studies will 
allow us to identify the molecular circuits that ultimately 
determine morphogen-associated outputs. 
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